Pembrolizumab and EDP1503 in Advanced Melanoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Melanoma
- Melanoma (Skin)
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03595683
- Collaborators
- Merck Sharp & Dohme Corp.
- Evelo Biosciences
- Investigators
- Principal Investigator: Jason Luke, MD University of Chicago
Get Well Soon